Program by Day

« Back

Print this page

	Personalized Program The Personalized Program enables you to compile an individual program with events and contributions of your interest. Therefore, it can be used very well to plan your actual congress visit at an early point of time. Please log in to use the Personalized Program.	» Login » Identification » Help

« previous day	Monday, 29. June 2009	next day »

No.	S-26 - Symposium
Time:	08.00-09.30
Room:	Blue Amphitheatre
Topic:	Other
Track:	2 Clinical
Session title:	New approaches to diagnostics and treatment in personality disorders
	Sabine Herpertz, Germany	Chair
	Larry Siever, USA	Co-Chair

001	Changes in classifying personality disorders: New from the DSM-V task force
	Roel Verheul, Netherlands	Speaker
002	Schizotypal personality disorder: New data on imaging, genetics, and treatment
	Larry Siever, USA	Speaker
003	Differentiating subtypes of antisocial personality disorder by functional neuroimaging
	Sabine Herpertz, Germany	Speaker
004	Psychotherapeutic treatment guidelines in personality disorders
	Klaus Lieb, Germany	Speaker

No.	S-27 - Symposium
Time:	08.00-09.30
Room:	Salle Maillot
Topic:	Neuroimaging
Track:	1 Basic
Session title:	Positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) of human brain monoamine neurotransmission
	Nicole Praschak-Rieder, Austria	Chair
	Nathalie Ginovart, Switzerland	Co-Chair

001	Influence of Fenfluramine challenge of Serotonin-2A receptor binding
	Franz Vollenweider, Switzerland	Speaker
002	Effects of SSRIs on brain serotonin function revealed by PET and phfMRI
	Rupert Lanzenberger, Austria	Speaker
003	Brain monoamino-oxidase-A imaging using [11C]harmine and positron emission tomography
	Nathalie Ginovart, Switzerland	Speaker
004	Influence of season and light on human serotonin transporter binding and function
	Matthaeus Willeit, Austria	Speaker

No.	S-28 - Symposium
Time:	08.00-09.30
Room:	Room 352AB
Topic:	Affective Disorders (Unipolar)
Track:	1 Basic
Session title:	Neurobiology of sleep regulation and sleep deprivation and consequences for depression and somatic health
	Axel Steiger, Germany	Chair
	Edith Holsboer-Trachsler, Switzerland	Co-Chair

001	Sleep and neuroendocrine biomarkers as predictors for psychic health and depressive illness course in children and adults
	Martin Hatzinger, Switzerland	Speaker
002	Neuropeptidergic regulation of sleep and sleep deprivation
	Petra Schüssler, Germany	Speaker
003	Neurotransmitter regulation of sleep deprivation in depression
	Ulrich-Michael Hemmeter, Switzerland	Speaker
004	The consequences of chronically disrupted and restricted sleep: Insights from experimental studies in animals and relevance for depression
	Peter Meerlo, Netherlands	Speaker

No.	S-29 - Symposium
Time:	08.00-09.30
Room:	Room 252B
Topic:	Psychopharmacology
Track:	2 Clinical
Session title:	Antipsychotic treatment of aggression in the intellectually disabled - a growing controversy
	David Janowsky, USA	Chair
	Sherva Elizabeth Cooray, United Kingdom	Co-Chair

001	Antipsychotic withdrawal induced activation of aggression in the intellectually disabled
	David Janowsky, USA	Speaker
002	Evidence for the effectiveness of antipsychotic medications to manage problem behaviors in adults with intellectual disability
	Shoumitro Deb, United Kingdom	Speaker
003	Antipsychotic agents in the treatment of autism
	David Posey, USA	Speaker
004	The argument against antipsychotic agents in the intellectually disabled
	Sherva Elizabeth Cooray, United Kingdom	Speaker

No.	S-30 - Symposium
Time:	08.00-09.30
Room:	Room 241
Topic:	Genetics
Track:	1 Basic
Session title:	Translational research in the neurogenetics of NPY
	Aleksander Mathe, Sweden	Chair
	Andreas Reif, Germany	Co-Chair

001	Distribution of NPY and its receptors: Significance for anxiety/depression and neurogenesis
	Aleksander Mathe, Sweden	Speaker
002	Effects of viral vector-induced overexpression of neuropeptide Y and Y2 receptors in seizure models
	David Woldbye, Denmark	Speaker
003	NPY and its receptor genes in personality disorder
	Andreas Reif, Germany	Speaker
004	Molecular genetic evidence for a 4q31-34 panic disorder risk locus
	Katharina Domschke, Germany	Speaker

No.	S-31 - Symposium
Time:	08.00-09.30
Room:	Room 251
Topic:	Childhood Adolescent Disorder
Track:	2 Clinical
Session title:	ADHD in adults: Comorbidity aspects and the therapeutic issues
	Joseph Biederman, USA	Chair
	Jacques Bouchez, France	Co-Chair

001	The 5-HTTLPR-S/s Genotype increases the risk for depression and anxiety disorders in youth with ADHD when exposed to parental depression: A gene-environment interaction study
	Joseph Biederman, USA	Speaker
002	Gender effect in response to methylphenidate treatment in adults with ADHD
	Thomas Spencer, USA	Speaker
003	Cigarette smoking and ADHD : A review and new pharmacotherapies perspectives
	Herve Caci, France	Speaker
004	Impulsivity in adult ADHD clinical subtypes
	Jacques Bouchez, France	Speaker

No.	FC-07 - Free Communications
Time:	08.00-09.30
Room:	Room 351
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders III
	Shigenobu Kanba, Japan	Chair
	Norbert Müller, Germany	Co-Chair

001	Can the writing of patients with schizophrenia be identified by means of automated computer-aided analysis?
	Rael Strous, Israel	Speaker
002	The relation between the general intellect of schizophrenic patients and psychopathological deterioration
	Eka Chkonia, Georgia	Speaker
003	Cannabis use and cognitive functioning in schizophrenia
	Antony Henderson, Australia	Speaker
004	Effects of cannabis use on cognitive deficits in first-episode psychosis
	Murat Yucel, Australia	Speaker
005	Association between neurocognitive factors and homicide in schizophrenia: A systematic review
	Stephane Richard-Devantoy, France	Speaker
006	Parameters of quantitative EEG correlate with negative symptoms in neuroleptic-naive patients with first episode schizophrenia
	Ronan Zimmermann, Switzerland	Speaker

No.	FC-08 - Free Communications
Time:	08.00-09.30
Room:	Room 242A
Topic:	Anxiety
Session title:	Anxiety I
	Alexander Neumeister, USA	Chair
	Brian Harvey, South Africa	Co-Chair

001	Neural and physiological phenotypes in zebrafish models of stress
	Allan Kalueff, USA	Speaker
002	PTSD symptom severity and co-morbid psychiatric disorders
	Usha Barahmand, Iran	Speaker
003	Balneotherapy in the treatment of generalized anxiety disorder
	Olivier Dubois, France	Speaker
004	Interleukin-18 initiates goblet cell-dependent mucosal barrier dysfunction of the mouse rectum in response to psychosocial stress
	Kensei Nishida, Japan	Speaker
005	Effects of the dorsal hippocampal opioidergic system in the modulation of anxiety
	Jalal Solati, Iran	Speaker

No.	FC-09 - Free Communications
Time:	08.00-09.30
Room:	Room 242B
Topic:	Neurodegenerative Disorders
Session title:	Neurodegenerative Disorders
	Cornelius Katona, United Kingdom	Chair
	Anne Eckert, Switzerland	Co-Chair

001	Effects of Chinese herb Danshen-Dahuang on learning, memory ability and hippocampal gene expression of APP, PS1, BACE in rats with Alzheimer disease
	Bai Han, China, People's Republic of	Speaker
002	Relations of regional cerebral perfusion, atrophy and functional genetic variants in mild cognitive impairment (MCI) and Alzheimer’s disease (AD)
	Christian Luckhaus, Germany	Speaker
003	Centers of interest in Alzheimer patients, focus on apathy
	Daniel Dachesky, Argentina	Speaker
004	Brain iron accumulation as a risk factor for neurodegenerative disorders
	George Bartzokis, USA	Speaker
005	The clinical and neurobiological overlap between the major psychoses and frontotemporal dementia: More than a frontotemporal coincidence?
	Dennis Velakoulis, Australia	Speaker
006	Subthalamic neuronal activity in patients with obsessive-compulsive disorders or parkinson's disease
	Marie-Laure Welter, France	Speaker

No.	PL-02 - Plenary Lecture
Time:	09.45-10.30
Room:	Main Amphitheatre
Topic:	Brain Function
Session title:	Globalization, market and brain sciences
	Robertas Bunevicius, Lithuania	Chair

001	Globalization, markets and the brain sciences
	Peter Whybrow, USA	Speaker

No.	YS-02 - Young Scientists Award Session
Time:	09.45-10.30
Room:	Room 242A
Topic:	Genetics
Session title:	Genetics
	Rainald Mössner, Germany	Chair
	Lynn E. DeLisi, USA	Co-Chair

001	Interaction of psychological, neurocognitive and genetic risk factors in the background of suicidal behaviour
	Andrea Szkaliczki, Hungary	Speaker
002	Association of a serotonin receptor 2A gene polymorphism on cognitive function in early-onset schizophrenia and their unaffected relatives
	Nora S. Vyas, United Kingdom	Speaker
003	A genetic modifier of human aggression and anger control
	Björn Schott, Germany	Speaker

No.	TG-03 - WFSBP Treatment Guidelines
Time:	11.00-12.30
Room:	Room 242A
Topic:	Other
Session title:	Personality disorders
	Alexandre Dailliet, Belgium	Chair

	Sabine Herpertz, Germany	Presenter
	Larry Siever, USA	Presenter

No.	SL-01 - Special Lecture
Time:	11.00-12.00
Room:	Blue Amphitheatre
Topic:	Other
Session title:	Financial and non-financial conflicts of interest in psychiatry
	Nicolas Moore, France	Chair

001	Financial and non-financial conflicts of interests in psychiatry
	Mario Maj, Italy	Speaker

No.	D-03 - Debate
Time:	11.00-12.30
Room:	Room 351
Topic:	Psychopharmacology
Session title:	Should we keep using benzodiazepine?
	Jean-Pierre Lepine, France	Chair

	Christer Allgulander, Sweden	Proponent
	Mathias Berger, Germany	Opponent

No.	W-05 - Workshop
Time:	11.00-12.30
Room:	Room 242B
Topic:	Other
Session title:	The development of biological psychiatry in the developing world
	Pichet Udomratn, Thailand	Chair

001	Teaching and training of biological psychiatry in the developing world
	Saroja Krishnaswamy, Malaysia	Speaker
002	The progress of biological psychiatry in the asian subcontinent
	Anu Kant Mital, India	Speaker

No.	S-32 - Symposium
Time:	11.00-12.30
Room:	Salle Maillot
Topic:	Neurodegenerative Disorders
Track:	3 Interface
Session title:	Depression and dementia: Stress hormones and neuroprotection
	Edith Holsboer-Trachsler, Switzerland	Chair
	Luc Staner, France	Co-Chair

001	Role of neurosteroids and oxidative stress in neurodegeneration
	Anne Eckert, Switzerland	Speaker
002	Neuropeptide regulation and sleep in aging and depression
	Axel Steiger, Germany	Speaker
003	Can hormones provide natural neuroprotectivity: Melatonin and estrogen in neurodegeneration?
	Egemen Savaskan, Switzerland	Speaker
004	Antidepressants, age related sleep alterations and depression
	Luc Staner, France	Speaker

No.	S-33 - Symposium
Time:	11.00-12.30
Room:	Room 352AB
Topic:	Other
Track:	1 Basic
Session title:	Peripartum mood disorders: From physiological to pathophysiological adaptations
	Inga D. Neumann, Germany	Chair
	Cort Pedersen, USA	Co-Chair

001	Adaptations of stress responses in peripartum women: Implications for psychiatric illness
	Margaret Altemus, USA	Speaker
002	Late pregnancy thyroid status: Relationships to perinatal depression in women and a rat model
	Cort Pedersen, USA	Speaker
003	Chronic psychosocial stress in pregnancy: Towards an animal model of postpartum depression
	Inga D. Neumann, Germany	Speaker
004	Social support, stress perception and maternal depressive symptoms during pregnancy: Effects on fetal health
	Petra Arck, Germany	Speaker

No.	S-34 - Symposium
Time:	11.00-12.30
Room:	Room 252B
Topic:	Affective Disorders (Unipolar)
Track:	1 Basic
Session title:	Identifying biomarkers of depression: New insights from animal models
	Igor Branchi, Italy	Chair
	Mathias Schmidt, Germany	Co-Chair

001	Early environment shapes vulnerability to psychopathology in animal models of depression: Is altered metabolism a reliable biomarker?
	Igor Branchi, Italy	Speaker
002	Markers of neuronal network plasticity in mood disorders and antidepressant response
	Eero Castren, Finland	Speaker
003	Novel strategies to discover susceptibility and resilience biomarkers for stress-induced diseases
	Mathias Schmidt, Germany	Speaker
004	From inflammation to depression: A role for indoleamine 2,3 dioxygenase
	Robert Dantzer, USA	Speaker

No.	S-35 - Symposium
Time:	11.00-12.30
Room:	Room 241
Topic:	Addictive Disorders
Track:	3 Interface
Session title:	Behavioral addictions: Neurobiology and treatment
	David A. Gorelick, USA	Chair
	Aviv Weinstein, Israel	Co-Chair

001	The neuropsychopharmacology of pathological gambling
	Marc Potenza, USA	Speaker
002	Compulsive buying
	Michel Lejoyeux, France	Speaker
003	Sexual addiction and paraphilias
	Florence Thibaut, France	Speaker
004	Dopamine release during computer game playing
	Aviv Weinstein, Israel	Speaker

No.	S-36 - Symposium
Time:	11.00-12.30
Room:	Room 251
Topic:	Psychotic Disorders
Track:	3 Interface
Session title:	Psychophysiological endophenotypic makers in prodromal and first-episode schizophrenia patients
	Birte Glenthoj, Denmark	Chair
	Raquel Gur, USA	Co-Chair

001	Endophenotype candidacy of key psychophysiological disturbances in schizophrenia
	Raquel Gur, USA	Speaker
002	Deficits in prepulse Inhibition in the prodrome of schizophrenia
	Boris Quednow, Switzerland	Speaker
003	Effects of a six month antipsychotic treatment on sensory(motor) gating and its neural generators: A longitudinal study of antipsychotic-naive first-episode schizophrenic patients
	Bob Oranje, Denmark	Speaker
004	Vulnerability markers in the prodrome in early psychosis: Predicting outcome and understanding the mechanism
	Kristin Cadenhead, USA	Speaker

No.	FC-10 - Free Communications
Time:	12.30-14.00
Room:	Room 351
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders IV
	Werner Strik, Switzerland	Chair
	Nash Boutros, USA	Co-Chair

001	D2/3-Receptor availability in schizophrenia decreases with progression of psychosis: An [18F] Fallypride Study
	Ingo Vernaleken, Germany	Speaker
002	Increased EEG sources (LORETA) in the left hemisphere of sinistral male schizophrenics and in the right hemisphere of dextral male schizophrenics
	Pierre Flor-Henry, Canada	Speaker
003	Erythrocyte membrane fatty acids and transition to psychosis in ultra-high risk individuals: Basic research findings from a RCT
	G. Paul Amminger, Australia	Speaker
004	Impaired predictive component of smooth pursuit in schizophrenia
	Irene Nkam, France	Speaker
005	Neurocognitive impairments among first-epidode psychotic patients without drug consumption
	Irene Vanelli, Portugal	Speaker
006	State and trait aspects of auditory oddball event-related potentials in schizophrenia
	Irina Lebedeva, Russia	Speaker
007	The clinical correlate of neurological soft signs in an epidemiologically representative sample of first episode psychosis patients. Evidence from the Picos Veneto study
	Sarah Tosato, Italy	Speaker

No.	FC-11 - Free Communications
Time:	12.30-14.00
Room:	Room 242A
Topic:	Affective Disorders (Bipolar)
Session title:	Affective Disorders (Bipolar)
	Frank Bellivier, France	Chair
	Francesc Colum, Spain	Co-Chair

001	How often bipolar disorder merges after a diagnosis of unipolar depression?
	Ruby Castilla-Puentes, USA	Speaker
002	Women with bipolar disorder: Clinical challenges
	Ruth Baruch, Canada	Speaker
003	Do psychotic symptoms in mania predict later course of bipolar disorder?
	Diego Novick, United Kingdom	Speaker
004	Cognitive Behavior Therapy (CBT) versus Psychoeducation (PE) in bipolar disorder: A randomized controlled study
	Gerhard Lenz, Austria	Speaker
005	Cross-prevalence of migraine and bipolar disorder
	Abigail Ortiz-Dominguez, Canada	Speaker
006	Cognitive emotion regulation and inhibitory mechanisms in bipolar disorder and schizophrenia
	Melissa Green, Australia	Speaker

No.	FC-12 - Free Communications
Time:	12.30-14.00
Room:	Room 242B
Topic:	Genetics
Session title:	Genetics I
	Shinichiro Nanko, Japan	Chair
	Aleksander Mathe, Sweden	Co-Chair

001	Finger ratio differences and psychological traits: A case for epigenetics?
	Yu-Sang Lee, Korea, Republic of	Speaker
002	mRNA expression of candidate genes are blood biomarkers for major depression
	Raoul Belzeaux, France	Speaker
003	Dopamine and Cannabinoid receptors gene alterations and high impulsivity between two strains of mice
	Francisco Navarrete, Spain	Speaker
004	Association study of tryptophan hydroxylase 2 gene in bipolar patients with panic disorder comorbidity
	Humberto Correa, Brazil	Speaker
005	Genetic disease and mental health
	Paula Santos, Portugal	Speaker
006	The role of cGMP-nitric oxide pathway on learning and memory in rats
	Ipek Komsuoglu Celikyurt, Turkey	Speaker

No.	P-12 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Addictive Disorders
Session title:	Addictive Disorders II
	Franck Bayle, France	Chair

001	Smoking is associated with psychosis
	Renaud de Beaurepaire, France	Presenter
002	Concurrent disorders: Substance use disorders, eating disorders, and post-traumatic stress disorders
	Christine Courbasson, Canada	Presenter
004	Influence of acute hemoexfusion on severity and length of withdrawal syndrome in heroin addiction
	E. N. Krivulin, Russia	Presenter
005	Cigarettes smoking, lipid profile and paraoxonase 1 activity
	Haj Mouhamed Dhouha, Tunisia	Presenter
006	Psychopharmacotherapy of pathological gambling comorbid with affective disorder
	D. Chetverikov, Russia	Presenter
007	Assessing the psychometric properties of the 6th Brazilian version of the Addiction Severity Index (ASI 6): Family-social area
	Laisa Sartes, Brazil	Presenter
008	Common pathogenetic mechanisms of alcoholic and food addiction
	Marina Chukhrova, Russia	Presenter
009	Naltrexone for the treatment of amphetamine dependence: A randomized placebo controlled trial
	Nitya Jayaram-Lindström, Sweden	Presenter
013	Treatment of sleep disturbances in the alcohol dependence - comparative effects of Zolpidem vs. Benzodiazepines hypnotics
	Meri Jakovcevska-Kujundziska, Macedonia, The former Yugoslav	Presenter
014	Differences in use of wait-and-see strategy in the stop signal task between non-chemical and chemical addictions
	Pinhas Dannon, Israel	Presenter
015	Sensitivity of the dopaminergic neurotransmision to opioidergic stimulation in alcoholism: A PET study with [18F] fallypride
	Michael Paulzen, Germany	Presenter
016	Impairment in the prepulse inhibition (PPI) in abstinent alcoholics
	Gabriel Rubio, Spain	Presenter
017	Considerations about the influence of age and duration of opiate use on the condition and symptoms of opiate addicts
	Peter Hermann, Austria	Presenter
018	Epidemiological characteristics of clinicaly treated heroin addicts
	Abdurahman Kuldija, Bosnia and Herzegovina	Presenter
019	Addictive disorder
	Adebowale Yusuf Adedoja, Nigeria	Presenter
020	Effects of methadone therapy on changing of positive and negative mood affect in addicted
	Seyed Jalal Mosavi Amiri, Iran	Presenter
021	What is the first cause of tendency to addiction? Psychological, environmental or physical
	Seyed Jalal Mosavi Amiri, Iran	Presenter

No.	P-13 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Affective Disorders (Bipolar)
Session title:	Affective Disorders (Bipolar) I
	Heinz Grunze, United Kingdom	Chair

001	Validity of the “National Institutes of Mental Health Life Chart – self version” (NIHM-sLCM)
	Christoph Born, Germany	Presenter
002	Lamotrigine in the treatment of bipolar disorder in women of reproductive age
	Natalie Rasgon, USA	Presenter
003	Differences in clinical features between bipolar I and II disorders
	Ji-Hyun Baek, Korea, Republic of	Presenter
004	Subsyndromical symptoms as manifestation of alarm in the patients with bipolar disorder
	Desiree Harnic, Italy	Presenter
005	Late onset bipolar disorder differential characteristics
	Miguel Vega Pineiro, Spain	Presenter
006	Subclinical anxiety as an endophenotypic marker in Costa Rican bipolar I patients
	Javier Contreras, Costa Rica	Presenter
007	Bipolar disorder in patients with a current diagnosis of major depressive episode
	Jean-Michel Azorin, France	Presenter
008	A naturalistic study of olanzapine in the treatment of patients with manic or mixed episodes of bipolar disorder: Results from 12-weeks acute phase treatment with olanzapine in monotherapy and in combination
	Pavel Vohlidka, United Kingdom	Presenter
009	Neurological comorbidities in patients with bipolar disorder: A systematic review
	Julio Bobes, Spain	Presenter
010	Spatial working memory function in bipolar disorder and schizophrenia
	Marcela Barguil, USA	Presenter
011	Illness experience and reasons for non-adherence among individuals with bipolar disorder who are poorly adherent with medication
	Martha Sajatovic, USA	Presenter
012	Depressive symptom ratings in geriatric patients with type I bipolar mania
	Martha Sajatovic, USA	Presenter
013	Mood disorders associated with interferon treatment: Development and validation of a mood disorders diagnostic screening questionnaire: The DETHEC questionnaire
	Martin Patrick, France	Presenter
014	Impact of psychoeducation in bipolar disorder on the quality of life
	Radhouene Kachouri, Tunisia	Presenter
015	Monotherapy with olanzapine of acute manic episode
	Christos Istikoglou, Greece	Presenter
016	ADHD and bipolar disorder: Prevalence of misdiagnosis?
	Juan Carlos Navarro Barrios, Spain	Presenter
017	Total agenesis of the corpus aallosum in a patient with a polymorphic clinical presentation
	Sandra Almeida, Portugal	Presenter
018	Lamotrigine associated rash in adult patients with bipolar i disorder: A multicenter, prospective, naturalistic, open-label trial
	Won-Myong Bahk, Korea, Republic of	Presenter
019	The efficacy of quetiapine in patients with bipolar depression: A multi-center, prospective, open-label, observational study(queen study)
	Won-Myong Bahk, Korea, Republic of	Presenter
020	Body Mass Index (BMI) correlates of bipolar disorder: Can BMI help predict prognosis and outcome?
	Cynthia Calkin, Canada	Presenter

No.	P-14 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Affective Disorders (Unipolar)
Session title:	Affective Disorders (Unipolar) II
	Goeran Hajak, Germany	Chair

001	Depression and body mass index in primary care patients: Impact of gender
	Adomas Bunevicius, Lithuania	Presenter
002	Association between major depressive disorder and anxiety disorder and heart rate variability in the Netherlands Study of Depression and Anxiety (NESDA)
	Carmilla Licht, Netherlands	Presenter
003	Evidence for sustained improvement in memory deficits following computer assisted cognitive remediation in patients with mood disorders
	Liesel-Anne Meusel, Canada	Presenter
004	Is „male-type” depression specific for females, too?
	Zoltan Rihmer, Hungary	Presenter
005	Psychopathological and neuropsychological profiles of primary major depression and post - traumatic brain injury major depression
	Massimo Carlo Mauri, Italy	Presenter
006	Clinical caracteristics of female depression patients in East - South Serbia
	Aleksandra Petrovic, Serbia and Montenegro	Presenter
007	New options in monitoring the course of depressive disorders: Development and validation of a short screening for depression (DESC) using Rasch analysis
	Christine Norra, Germany	Presenter
008	Experimental challenge studies of central monoamine systems in humans: Comparison of methodology and neurophysiological effects
	Christine Norra, Germany	Presenter
009	Adrenal and thyroid axis activity and FT4 / FT3 ratio in depression
	Marie-Claude Mokrani, France	Presenter
010	Chronobiological HPA axis dysfunction in depression
	Marie-Claude Mokrani, France	Presenter
011	Dopamine function and cortisol secretion in depression
	Fabrice Duval, France	Presenter
012	Investigating the impact of spiritual therapy in treatment of depression (with emphasis on the Islamic Tradition)
	Ali Naghi Faghihi, Iran	Presenter
013	Depression and Omega-3 fatty acids in the general population of Greece: A preliminary study
	Greta Wozniak, Greece	Presenter
014	Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD)
	Heikki Katila, Finland	Presenter
015	Fluvoxamine induces the phosphorylation of Akt - 1 in PC12 cells
	Miho Nakano, Japan	Presenter
016	Attentional impairments in depression: Impact of depression sub-type and severity
	Andrew Kemp, Australia	Presenter
017	Depressive comorbidity in patients candidates to epileptic surgery
	Luis Pestana, Portugal	Presenter
018	QEEG prediction of response to rTMS and/or venlafaxine in patients with depressive disorder. A double-blind, single-centre, randomized study
	Martin Brunovsky, Czech Republic	Presenter
019	Brain-derived neurotrophic factor plasma level is reduced in antidepressant-free patients with late-onset depression
	Breno Diniz, Brazil	Presenter
020	Recovery from trauma-related major depression and bipolar disorder
	Ion Draghinda, Switzerland	Presenter
021	Deviant stress responses in girls at risk for familial depression. The TRAILS Study
	Esther Bouma, Netherlands	Presenter

No.	P-15 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Childhood Adolescent Disorder
Session title:	Childhood & Adolescent Disorders II
	David Cohen, France	Chair

001	The effects of Adderall XR on driving in adolescents with Attention-Deficit-Hyperactivity Disorder
	Grazyna Jackiewicz, Canada	Presenter
002	Assessment of psychopathological characteristics of children with complex neurological dysfunction
	Elodie Zviadadze, France	Presenter
003	Creative and developmentally sensitive approaches to treating Needle Phobia in a tertiary paediatric hospital setting
	Rubina Khan, Australia	Presenter
004	Differences in hypothalamic-pituitary-adrenal axis functioning among children with ADHD predominantly inattentive and combined types
	Stephan Claes, Belgium	Presenter
005	Attachment and genetics in ADHD children: Insecure attachment as a risk factor for comorbidities
	Ximena Carrasco, Chile	Presenter
006	Treatment and psychosocial background in incarcerated adolescents from Austria, Turkey and former Yugoslavia
	Susanne Bauer, Austria	Presenter
008	Neurophysiological investigation of control mechanisms in children with Tourette syndrome
	Michael Siniatchkin, Germany	Presenter
009	Prediction of inattention symptoms at childhood to verbal and non-verbal working memory at adolescence
	Susan Shur-Fen Gau, Taiwan	Presenter
010	Peculiarity of diagnostics and treatment of early child schizophrenia on residual organic background
	Nina Iovchuk, Russia	Presenter
011	The terms of cessation of prophylactic psychotropic therapy by circular schizophrenia in children and adolescents
	Nina Iovchuk, Russia	Presenter
012	The dopamine deficit theory of Attention-deficit/Hyperactivity disorder (ADHD) needs re-examining
	Francois Gonon, France	Presenter
013	Behavior of ADHD children playing video games
	Stéphanie Bioulac, France	Presenter
014	French version of The Liebowitz Social Anxiety Scale for children and adolescents: A pilot study
	Stéphanie Bioulac, France	Presenter
015	An open-label study of treatment of the early-onset bipolar disorders with risperidone long-acting injection
	Miguel Boarati, Brazil	Presenter
016	Psychotic disorder in childhood: A case report
	Maria Manuela Soares, Portugal	Presenter
017	Behavior of the children with cochlear implant
	Svetlana Slavnic, Serbia and Montenegro	Presenter
018	A comparative study of disability among patients suffering social anxiety disorder and comorbid depressive disorders
	Tarek Molokhia, Egypt	Presenter
019	Clinical and epidemiological study of parentally-deprivedprimary school children in Alexandria
	Tarek Molokhia, Egypt	Presenter
020	Comorbidity of eating disorders among patients with bipolar disorders
	Tarek Molokhia, Egypt	Presenter

No.	P-16 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders III
	Bernhard Bogerts, Germany	Chair

001	Adjunctive Aripiprazole: A good strategy for Clozapine induced metabolic syndrome
	Michel Soufia, Lebanon	Presenter
002	The effect of weight loss on obesity-related quality of life and body image in obese schizophrenic patients
	Bo-Hyun Yoon, Korea, Republic of	Presenter
003	Hypersensitivity to MK-801 - induced hyperlocomotion in a neurodevelopmental model for schizophrenia: Reversal by antipsychotics
	Gwenaëlle Le Pen, France	Presenter
004	Effects of olanzapine-treatment on cell mitotic activity in the hypothalamus and adipose tissue of mice
	Yamauchi Takahira, Japan	Presenter
005	A randomized controlled study of cognitive remediation in schizophrenia (RECOS: Cognitive Remediation in Schizophrenia vs CRT: Cognitive Remediation Therapy)
	Gabrielle Chesnoy, France	Presenter
006	Apathy and cognition in schizophrenia
	Georgios Konstantakopoulos, Greece	Presenter
007	Mentalizing and awareness of illness in schizophrenia
	Georgios Konstantakopoulos, Greece	Presenter
008	Effect of carbamazepine on behavioral troubles with schizophrene patient
	Grégoire Magloire Gansou, Benin	Presenter
009	Synaptosomal-associated protein (snap-25) polymorphisms and response to olanzapine in schizophrenia patients
	Hasan Herken, Turkey	Presenter
010	Changes in oxy - hemoglobin during emotionally loaded shiritori task in schizophrenic patients evaluation by NIRS
	Kiichiro Morita, Japan	Presenter
011	Characteristics of emotional charged P300 component in patients with schizophrenia: Comparison with healthy controls
	Keiichiro Mori, Japan	Presenter
012	Omega-3 fatty acids reduce serum triglyceride levels in individuals at ultra-high risk for psychosis
	Konstantinos Papageorgiou, Austria	Presenter
013	Inspection time, intelligence and cognition in schizophrenia
	Linley Denson, Australia	Presenter
014	Source monitoring seems to be more affected in paranoid than in non-paranoid schizophrenia
	Monica N. Toba, France	Presenter
015	Translational modeling of the asenapine plasma concentration dopamine D2 receptor occupancy relationship in rats and humans
	Mohammed Shahid, United Kingdom	Presenter
016	Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: Possible relevanceto neuroprotective interventions in Schizophrenia
	Tsung-Tsair Yang, Taiwan	Presenter
017	Niacin sensitvity different in people at risk to develop psychosis and in first-episode schizophrenia patients
	Stefan Smesny, Germany	Presenter
018	Niacin sensivity, membrane fatty acids and phospholipase A2 activity: Associations in people at rist to develop psychosis
	Stefan Smesny, Germany	Presenter
019	Frontal lobes MRI-peculiarities and auto antibodies to nerve growth factor (NGF) in families of patients with schizophrenia
	Natalia Efanova, Russia	Presenter

No.	P-17 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders IV
	Veronica Larach-Walters, Chile	Chair

001	Psychological and neuropsychological similarities and discrepancies of triplets suffering from atypical schizophrenia
	Dimitrios Dikeos, Greece	Presenter
002	Study of schizophrenia
	Andrey Starytsyn, Russia	Presenter
003	The impact of smoking on the schizophrenic relapses
	Gavril Cornutiu, Romania	Presenter
004	Hypofrontality and the frontal-striata-thalamic pathway during varied attentional tasks in schizophrenia
	Monte Buchsbaum, USA	Presenter
005	Olanzapine orally disintegrating tablets cause no moresedation than standard tablets in a small outpatient sample
	Emmanuil Patelaros, Greece	Presenter
006	Traumatic brain injury and secondary psychosis
	Rachel Batty, Australia	Presenter
007	Relation of 18F-fallypride binding potential and antipsychotic treatment response in patients with schizophrenia
	Monte Buchsbaum, USA	Presenter
008	The effect of ketamine on behavior and quantitative EEG - an animal model of psychosis
	Tomas Palenicek, Czech Republic	Presenter
009	Public mistrust of DNA biobank studies in Malaysia
	Han Chern Loh, Malaysia	Presenter
010	Where does evidence from new trials for schizophrenia fit with the existing evidence: A case of the Emperor’s new clothes?
	Mahesh Jayaram, United Kingdom	Presenter
011	HPA axis functioning in schizophrenic patients
	Mário Simões, Portugal	Presenter
012	Association between the leukemia inhibitory factor gene and schizophrenia and cognitive functions
	Yuko Okahisa, Japan	Presenter
013	Neurocognitive deficits in schizophrenia measured by the Cambridge Neuropsychological Test Automated Battery
	Nóra Domján, Hungary	Presenter
014	Auditory mismatch negativity deficits in long-term heavy cannabis users
	Patrik Roser, Germany	Presenter
015	The conscious mind and quantum mechanics
	Fernando Corona, Mexico	Presenter
016	Water poisoning with SCH patients in conjunction with psychotic perceptions
	Snjezana Ler, Bosnia and Herzegovina	Presenter
017	Neuropsychological functioning and plasma levels of homocysteine in early - onset schizophrenia forensic patients compared with adult - onset - schizophrenia forensic patients and normal controls
	Konstanze Dorothea Römer, Switzerland	Presenter
018	Preliminary study of ABO blood group distribution in schizophrenia
	Pek Yee Tang, Malaysia	Presenter
019	Role of carotenoid level in schizophrenia
	Han Chern Loh, Malaysia	Presenter

No.	P-18 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Brain Function
Session title:	Brain Function II
	Pierre Baumann, Switzerland	Chair

001	Analysis of a novel, stress-inducible transcript in the mouse brain
	Claudia Liebl, Germany	Presenter
002	Two types of personality changes due to brain damage: A case-control study
	Samvel Margaryan, Armenia	Presenter
004	Oxidative and antioxidative capacity in LPS treated mice
	Hans-Willi Clement, Germany	Presenter
005	To the role of hydrogensulfide in psychiatric disorders: A preliminary study in mice
	Hans-Willi Clement, Germany	Presenter
006	Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the acquisition and extinction of inhibitory avoidance
	Irit Akirav, Israel	Presenter
008	Neurotoxic trace elements in bipolar disorder
	Kazuhiro Tajima Pozo, Spain	Presenter
009	Matrix Metalloproteinases in the Cerebrospinal fluid of suicide attempters
	Shorena Janelidze, Sweden	Presenter
010	The role of Urocortin peptides in regulating the central stress response: Evidence from a novel Urocortin triple knockout mouse model
	Michael Tsoory, Israel	Presenter
011	GABAergic neurons in the lateral habenula regulate anxiety-related behabior via the serotonergic raphe neurons
	Konno Kohtarou, Japan	Presenter
012	Abnormal cortical morphology in offenders with psychopathy
	Marina Boccardi, Italy	Presenter
013	Abnormal hippocampal shape in offenders with psychopathy
	Marina Boccardi, Italy	Presenter
014	Pattern of cerebral anomalies in older persons with schizophrenia and Alzheimer’s disease
	Marina Boccardi, Italy	Presenter
015	Structural brain pathology and violent crime: Revisiting a possibly underestimated factor
	Kolja Schiltz, Germany	Presenter
016	Mediation of anticonvulsant effect of Locus Coeruleus via noradrenergic and galaninergic transmissions
	Nino Kuchiashvili, Georgia	Presenter
017	The reoencephalophy characteristic of the vascular channel at patients discirculatory Encephalopathy
	Sergey Radchenko, Ukraine	Presenter
018	Patterns of cognitive dysfunction in first psychosis episode and borderline personality disorder: A comparative neuropsychological study
	Kazuhiro Tajima Pozo, Spain	Presenter
019	Theta - burst repetitive transcranial magnetic stimulation of the motor cortex improves obsessive compulsive disorder: Preliminary findings of an open - label study
	Andrei Radtchenko, France	Presenter
020	Types of immune imbalance in patients with neurotic disorders
	Irina Kupriyanova, Russia	Presenter
021	A single session of temporo-parietal transcranial magnetic stimulation - may improve dyslexia
	Marco Antonio Marcolin, Brazil	Presenter

No.	P-19 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Neuroimaging
Session title:	Neuroimaging I
	Dieter F. Braus, Germany	Chair

001	FDG - PET imaging of patients with amnestic mild cognitive impairment with and without depression
	Effie Mitsis, USA	Presenter
002	Using Effective Connectivity as a marker for Depression Vulnerability
	Christian Kasess, Austria	Presenter
003	Volitional saccades and prefrontal cortical activation in young people at ultra-high risk of psychosis
	Elizabeth Bowman, Australia	Presenter
004	Dissociation of neural networks for anticipation and consumption of social and non-social rewards
	Katja Spreckelmeyer, Germany	Presenter
005	The pathophysiology of schizophrenia: Evidence by Voxel-Based Morphometry and Diffusion Tensor Imaging
	Georgia Karoutzou, Germany	Presenter
006	Progressive MRI findings in schizophrenia
	Jannis Nimatoudis, Greece	Presenter
007	Cortical activations during auditory and non-auditory hallucinations: An fMRI study in childhood- and adult-onset schizophrenia
	Renaud Jardri, France	Presenter
008	Groupage A.B.O, phenotype, rhesus, lewisand schizophrenia
	Benabbas Malik, Algeria	Presenter
009	Brain activation preceding auditory verbal hallucinations
	Kellly Diederen, Netherlands	Presenter
010	Gender differences in [123I]-ADAM binding to Serotonin Transporters in patients with Major Depression before and after treatment with Citalopram
	Konrad Uebelhack, Germany	Presenter
011	Structural differences of gray matter between patients with unipolar and bipolar disorders assessed by voxel-based morphometric analysis
	Yong-Sheng Chen, Taiwan	Presenter
012	Longitudinal changes in brain structure following the first episode of psychosis
	Pilar de Castro Manglano, Spain	Presenter
013	Working memory dysfunction in obsessive - compulsive disorder: A neuropsychological and functional MRI study
	Tomohiro Nakao, Japan	Presenter
014	Disruption of white matter integrity in generalized anxiety disorder: A diffusion weighted imaging study
	Monica Baiano, Italy	Presenter
015	Six months follow-up study of brain levels of γ-aminobutyric acid, glutamate, and glutamine in the first episode schizophrenia patients
	Naoki Goto, Japan	Presenter
016	The neural basis of inhibiting one’s own perspective in psychosis proneness: An fMRI study
	Lisette van der Meer, Netherlands	Presenter
017	Attentional bias and vulnerability for depression: An fMRI study
	Katarina Dedovic, Canada	Presenter
018	The gray matter volume would predict the symptoms change in the patients with major depressive disorder: Mirtazapine vs SSRI
	Sun-Mi Kim, Korea, Republic of	Presenter
019	The neurocircuits in the social anxiety spectrum: A voxel-based investigation
	Maria Ferrari, Brazil	Presenter
020	Regional differences in validity of serotonin transporter occupancy values using PET
	Ulrike Moser, Austria	Presenter

No.	P-20 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Psychopharmacology I
	Robertas Bunevicius, Lithuania	Chair

001	Mirtazapine and sertraline in pregnancy and lactation
	Bettina Schletterer, Austria	Presenter
002	Assessment of 3-methoxy-4-hydroxyphenylglycol (MHPG), cortisol and cognitive performance in patients with anxiety, neuroticism and allostatic load, under treatment with alprazolam
	Carlos Alberto Soria, Argentina	Presenter
003	Cycloserine and fluvoxamine combined pharmacotherapy of refractory obsessive-compulsive disorder (OCD) among adolescents
	Maruke Yeghiyan, Armenia	Presenter
004	Decrease in benzodiazepine binding is a possible sign of fear and anxiety
	Ksenia Chekina, Russia	Presenter
005	New drugs elaboration for neurodegenerative disorders treatment based on KYNA - receptor binding mechanism
	Gennady Zakharov, Russia	Presenter
006	Influence of Solcoseryl on immune system and inflammatory-destructive processes in central nervous system in patients with cerebral arteriosclerosis
	Palamarchuk Iryna, Ukraine	Presenter
007	Effect of Methylphenidate - a point of view from a cell
	Jasmin Bartl, Germany	Presenter
008	Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of conditioned stress-induced ultrasonic vocalizations in rat
	Ronan Depoortere, France	Presenter
009	Immunological efficacy of preparation cytoflavin in therapy of borderline mental disorders
	Valentina Nikitina, Russia	Presenter
010	The use of atypical antipsychotic in Saudi Arabia
	Khalaf Aljumaah, Saudi Arabia	Presenter
011	Sexual dysfunction during risperidone and haloperidol treatment in schizophrenia
	Dragan Vukic, Serbia and Montenegro	Presenter
012	Clozapine withdrawal catatonia and neuroleptic malignant syndrome: A case report and literature review
	Magdalena Spariosu, USA	Presenter
013	Anticonvulsant activity and neurotoxicity of 3-(z)-[1-(aniline)ethylidene]-4,5-dihydrofuran-2(3h) - one derivatives in mice
	Christian Rodríguez, Venezuela	Presenter
014	Monotherapy versus antipsychotic combination in maintenance treatment of schizophrenia: Expirience from two wards in specialized psychiatric hospital "Gornja Toponica"
	Milan Stanojkovic, Serbia and Montenegro	Presenter
015	Agonism and inverse agonism at the benzodiazepine site of GABAA receptors: The influence on spontaneous locomotor activity and spatial memory
	Janko Samardzic, Serbia and Montenegro	Presenter
016	Drop - outs of patients in psychotherapy v/s patients in psychotherapy and pharmacotherapy
	Panagiotis Papadopoulos, Greece	Presenter
017	Task related adjustment of motorcortical excitability measured by transcranial magnetic stimulation (TMS) in normal adults pre and post methylphenidate (MPH) administration
	Johannes Buchmann, Germany	Presenter
018	Therapeutic Effects of Alpha-Lipoic Acid in Treatment of Diabetic Neuropathy
	Sibin Vladejic, Serbia and Montenegro	Presenter
019	Psychoneuroimmunomodulating effect of atypical neuroleptics
	Tamara Vetlugina, Russia	Presenter
020	Effects of Piracetam on brain BDNF, NMDA- and nicotinic receptor content in mice
	Julia Firstova, Russia	Presenter

No.	P-21 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Other
Session title:	Other I
	Gabriele Sachs, Austria	Chair

001	FAHR syndrome revealed by neuro - psychiatric disorders
	Abderrazzak Ouanass, Morocco	Presenter
002	Relationship between skin and psychopathology: Review of the literature
	Sami Richa, Lebanon	Presenter
003	Prevalence of psychiatric disorders during Peg - Interferon and Ribavirin therapy in patients with chronic hepatitis HCV - correlated
	Bernardo Dell’Osso, Italy	Presenter
004	Study oxidant and antioxidant systems in multiple sclerosis
	Natali Krotenko, Russia	Presenter
005	Temperament and character-myocardial infraction predisposed personality traits
	Dusan Petrovic, Serbia and Montenegro	Presenter
006	Features of application of psychotherapy in psychosomatic
	Elizabeth Pugach, Ukraine	Presenter
007	Investigation of job burnout between employees and managers
	Hossein Khanifar, Iran	Presenter
008	Studying the relationship between A & B personality types and managerial style
	Hossein Khanifar, Iran	Presenter
009	Studying the relationship between propensity to team - building and managers' personalities based on McKerry and Costa' Big-5 Model
	Mohamad Moghimi, Iran	Presenter
010	Application of "proteasome tolerance" to a novel therapy for neurodegerative diseases
	Takashi Kudo, Japan	Presenter
011	Time selective attention in a visual context. An event related potentials study
	Daniela Huerta, Chile	Presenter
012	Pathogenetic immunomodulating therapy in patients with neurotic disorders
	Roman Ahapkin, Russia	Presenter
013	Electroconvulsive therapy and schizophrenia
	Raquel Correia, Portugal	Presenter
014	Neuropsychiatric manifestations of HIV disease
	Rosa Rodrigues, Portugal	Presenter
015	Psychiatric symptoms associated with anabolic steroids and alimentary supplements
	Rosa Rodrigues, Portugal	Presenter
016	Oxidative stress and neuroprotection at experimentaly induced Parkinson's disease
	Arsen Zakaryan, Armenia	Presenter
018	Neurophysiological characteristics of patients with alcohol epileptic syndrome
	Tatiana Elistratova, Russia	Presenter
019	Application of ultralow temperatures in rehabilitation
	Uriy Liakh, Ukraine	Presenter

No.	FC-13 - Free Communications
Time:	14.00-15.30
Room:	Room 242A
Topic:	Brain Function
Session title:	Brain Function I
	Paul Cosyns, Belgium	Chair
	Nicole Praschak-Rieder, Austria	Co-Chair

001	Allelic variation in the serotonin transporter promoter modulates cortical excitability
	Goeran Hajak, Germany	Speaker
002	Lipopolysaccharide-induced free radical formation in the striatum of mice
	Hans-Willi Clement, Germany	Speaker
003	Optimise ECT techniques: The effects of pulse width manipulation on the amnesic side-effects of ECT treatment in depression
	Harm-Pieter Spaans, Netherlands	Speaker
004	Decreased BDNF serum levels in drug naïve non-depressed obsessive compulsive patients
	Luisella Bocchio-Chiavetto, Italy	Speaker
005	Verbal fluency and BDNF Val66Met polymorphism in schizophrenia
	Oussama Kebir, France	Speaker

No.	FC-14 - Free Communications
Time:	14.00-15.30
Room:	Room 242B
Topic:	Other
Session title:	Other II
	Pichet Udomratn, Thailand	Chair
	Arunas Germanavicius, Lithuania	Co-Chair

001	Suicide risk in relation to various psychiatric disorders
	Ping Qin, Denmark	Speaker
002	Insights into the suicidal mind
	Konrad Michel, Switzerland	Speaker
003	Thyroid axis activity and suicidal behavior in depressed patients
	Fabrice Duval, France	Speaker
004	HPT axis and personality traits in attempted suicide
	Jussi Jokinen, Sweden	Speaker
005	The effect of restricting access to a suicide jumping site
	Keren Skegg, New Zealand	Speaker
006	Psychiatric manifestations of Hashimoto’s disease/ encephalopathy
	Saadet Arda, Germany	Speaker

No.	SA-01 - Satellite Symposium
Time:	14.00-15.30
Room:	Blue Amphitheatre
Topic:	Depression: Basic / Clinical
Session title:	Treating depression - from neurobiology to clinical practice supported by an unrestricted educational grant from Lundbeck A/S.
	Roger S. McIntyre, Canada	Chair

001	The serotonergic system: the link to therapeutic efficacy?
	Brian E. Leonard, Ireland	Speaker
002	Optimising pharmacological treatment of depression in elderly patients
	Cornelius Katona, United Kingdom	Speaker
003	Optimising treatment outcome - keeping the patient in focus
	Roger S. McIntyre, Canada	Speaker

No.	SA-02 - Satellite Symposium
Time:	14.00-15.30
Room:	Salle Maillot
Topic:
Session title:	Pharmacological intervention in slow- wave sleep: a novel approach to the management of insomnia? supported by an unrestricted educational grant from Sanofi-Aventis
	Derk Jan Dijk, United Kingdom	Chair

001	Neurochemical aspects of sleep regulation with specific focus on slow-wave sleep
	Pierre Hervé Luppi, France	Speaker
002	Understanding SWS through neuro-imaging
	Pierre Maquet, Belgium	Speaker
003	Slow-wave sleep and the formation of memory
	Jan Born, Germany	Speaker
004	Slow-wave sleep deficiency and enhancement: implications for insomnia and its management
	Derk Jan Dijk, United Kingdom	Speaker

No.	TG-04 - WFSBP Treatment Guidelines
Time:	16.00-17.30
Room:	Room 242A
Topic:	Affective Disorders (Unipolar)
Session title:	Unipolar depression
	Peter Whybrow, USA	Chair

	Michael Bauer, Germany	Presenter
	Gerardo M. Heinze, Mexico	Presenter

No.	D-04 - Debate
Time:	16.00-17.30
Room:	Room 351
Topic:	Genetics
Session title:	Ethics of genetic testing of families for psychiatric deseases?
	Daniel Cohen, France	Chair

	Evan DeRenzo, USA	Proponent
	Arunas Germanavicius, Lithuania	Opponent

No.	W-06 - Workshop
Time:	16.00-17.30
Room:	Room 242B
Topic:	Stress: Basic / Clinical
Session title:	Animal models of major psychiatric disorders
	Inga D. Neumann, Germany	Chair

001	Animal models for anxiety and depression related diseases
	John Cryan, Ireland	Speaker
002	Animal models for gene X environment interactions shaping adult psychopathologies
	Aleksander Mathe, Sweden	Speaker

No.	S-37 - Symposium
Time:	16.00-17.30
Room:	Blue Amphitheatre
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	Psychoses at the interface between neurology and psychiatry
	Michael Trimble, United Kingdom	Chair
	Pierre Flor-Henry, Canada	Co-Chair

001	Epilepsy and psychosis - an epidemiological view
	Dale Hesdorffer, USA	Speaker
002	Psychosis, neurological soft signs and their meaning
	Paola Dazzan, United Kingdom	Speaker
003	Epilepsy and psychosis - anatomy and physiology
	Michael Trimble, United Kingdom	Speaker
004	On the question of the lateralization of epilepsy in the manic-depressive syndrome and depression
	Pierre Flor-Henry, Canada	Speaker

No.	S-38 - Symposium
Time:	16.00-17.30
Room:	Salle Maillot
Topic:	Neuroimaging
Track:	3 Interface
Session title:	Brain imaging in drug development: Traditional nosological versus endophenotype-directed approaches
	Gerhard Gründer, Germany	Chair
	Franz Vollenweider, Switzerland	Co-Chair

001	MRI-based endophenotyping as outset for drug targeting
	Franz Vollenweider, Switzerland	Speaker
002	From nosological to endophenotype-directed drug targeting: The role of PET
	Gerhard Gründer, Germany	Speaker
003	The role of PET in early risk discharge in CNS drug development
	Marc Laruelle, United Kingdom	Speaker
004	Enabling personalized medicine through novel imaging techniques in drug development
	Johannes Tauscher, USA	Speaker

No.	S-39 - Symposium
Time:	16.00-17.30
Room:	Room 352AB
Topic:	Affective Disorders (Bipolar)
Track:	1 Basic
Session title:	Genetic and environmental risk factors in early onset bipolar affective disorder
	Frank Bellivier, France	Chair
	Sven Cichon, Germany	Co-Chair

001	Whole genome association studies in bipolar I affective disorder
	Sven Cichon, Germany	Speaker
002	Candidate gene analyses in early onset bipolar affective disorder
	Bruno Etain, France	Speaker
003	Whole genome association analyses in early onset bipolar disorder
	Stephane Jamain, France	Speaker
004	Gene-environment interactions in early onset bipolar disorder
	Frank Bellivier, France	Speaker

No.	S-40 - Symposium
Time:	16.00-17.30
Room:	Room 252B
Topic:	Anxiety
Track:	3 Interface
Session title:	New insight into panic disorder
	Eduard Maron, Estonia	Chair
	David Nutt, United Kingdom	Co-Chair

001	Perspectives in research and treatment of panic disorder
	David Nutt, United Kingdom	Speaker
002	Challenge tests
	Jakov Shlik, Canada	Speaker
003	Genetics of panic disorder: New evidences
	Francis McMahon, USA	Speaker
004	Neuroimaging of panic disorder
	Eduard Maron, Estonia	Speaker

No.	S-41 - Symposium
Time:	16.00-17.30
Room:	Room 241
Topic:	Brain Function
Track:	1 Basic
Session title:	Metabolism of psychotropic drugs in the human brain: Possible relevance for their clinical profile?
	Pierre Baumann, Switzerland	Chair
	Viji Ravindranath, India	Co-Chair

001	Brain-specific expression of cytochrome P450 enzymes and their impact on metabolism of psychoactive drugs at the site of action
	Viji Ravindranath, India	Speaker
002	Brain Cyp 4Fs in brain injury and psychotropic drug metabolism
	Henry Strobel, USA	Speaker
003	Monoamine oxidase: A challenging enzyme and its drugs
	Peter Riederer, Germany	Speaker
004	Selective metabolism of psychotropic drugs by MAO-A and MAO-B in brain
	Pierre Baumann, Switzerland	Speaker

No.	S-42 - Symposium
Time:	16.00-17.30
Room:	Room 251
Topic:	Neurodegenerative Disorders
Track:	1 Basic
Session title:	Neurobiology of Alzheimer's disease: Beyond the amyloid hypothesis
	Orestes V. Forlenza, Brazil	Chair
	Russell H. Swerdlow, USA	Co-Chair

001	Alzheimer's disease, vascular dementia, or both?
	Donald R. Royall, USA	Speaker
002	The GSK-3 hypothesis of Alzheimer's disease
	Simon Lovestone, United Kingdom	Speaker
003	Phospholipids, phospholipase A2 and membrane abnormalities in Alzheimer's disease
	Wagner F. Gattaz, Brazil	Speaker
004	Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?
	Russell H. Swerdlow, USA	Speaker

No.	SA-03 - Satellite Symposium
Time:	18.00-19.30
Room:	Blue Amphitheatre
Topic:
Session title:	Agomelatine: A new therapeutic option for depressed patients supported by an unrestricted educational grant from Servier
	Michel Hamon, France	Chair
	Siegfried Kasper, Austria	Chair

001	Molecular mechanisms regulating the endogenous circadian clock
	Michael Hastings, United Kingdom	Speaker
002	A pharmacological breakthrough in the treatment of depression: the melatonergic approach
	Michel Hamon, France	Speaker
003	Agomelatine: Evidence-based antidepressant efficacy
	Pierre-Marie Llorca, France	Speaker
004	Management of depression with agomelatine
	Siegfried Kasper, Austria	Speaker

« previous day

Monday, 29. June 2009

next day »